Ropinirole for the treatment of early Parkinson's disease

C. H. Adler, K. D. Sethi, R. A. Hauser, T. L. Davis, J. P. Hammerstad, J. Bertoni, R. L. Taylor, J. Sanchez-Ramos, C. F. O'Brien

Research output: Contribution to journalArticle

259 Citations (Scopus)

Abstract

A prospective, randomized, placebo-controlled, double-blind, parallel- group, 6-month study assessed the efficacy and safety of ropinirole, a nonergoline D2-dopamine agonist, in patients with early Parkinson's disease (n = 241; Hoehn and Yahr stages I to III) with limited or no prior dopaminergic therapy. Patients (mean age, 62.8 years), stratified by concomitant use of selegiline, were randomized to ropinirole (n = 116) or placebo (n = 125). The starting dose of ropinirole was 0.25 mg tid with titration to at least 1.5 mg tid (maximum dose, 8 mg tid). Primary efficacy endpoint was the percentage improvement in Unified Parkinson's Disease Rating Scale (UPDRS) motor score. Ropinirole-treated patients had a significantly greater percentage improvement in UPDRS motor score than patients who received placebo (+24% vs -3%; p < 0.001). Ropinirole was well tolerated and patient withdrawals were infrequent. Most adverse experiences were related to peripheral dopaminergic activity. Ropinirole monotherapy is an effective and well-tolerated therapeutic option for treatment of early Parkinson's disease.

Original languageEnglish (US)
Pages (from-to)393-399
Number of pages7
JournalNeurology
Volume49
Issue number2
DOIs
StatePublished - Jan 1 1997

Fingerprint

Parkinson Disease
Placebos
Therapeutics
Selegiline
Dopamine Agonists
ropinirole
Safety

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Adler, C. H., Sethi, K. D., Hauser, R. A., Davis, T. L., Hammerstad, J. P., Bertoni, J., ... O'Brien, C. F. (1997). Ropinirole for the treatment of early Parkinson's disease. Neurology, 49(2), 393-399. https://doi.org/10.1212/WNL.49.2.393

Ropinirole for the treatment of early Parkinson's disease. / Adler, C. H.; Sethi, K. D.; Hauser, R. A.; Davis, T. L.; Hammerstad, J. P.; Bertoni, J.; Taylor, R. L.; Sanchez-Ramos, J.; O'Brien, C. F.

In: Neurology, Vol. 49, No. 2, 01.01.1997, p. 393-399.

Research output: Contribution to journalArticle

Adler, CH, Sethi, KD, Hauser, RA, Davis, TL, Hammerstad, JP, Bertoni, J, Taylor, RL, Sanchez-Ramos, J & O'Brien, CF 1997, 'Ropinirole for the treatment of early Parkinson's disease', Neurology, vol. 49, no. 2, pp. 393-399. https://doi.org/10.1212/WNL.49.2.393
Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J et al. Ropinirole for the treatment of early Parkinson's disease. Neurology. 1997 Jan 1;49(2):393-399. https://doi.org/10.1212/WNL.49.2.393
Adler, C. H. ; Sethi, K. D. ; Hauser, R. A. ; Davis, T. L. ; Hammerstad, J. P. ; Bertoni, J. ; Taylor, R. L. ; Sanchez-Ramos, J. ; O'Brien, C. F. / Ropinirole for the treatment of early Parkinson's disease. In: Neurology. 1997 ; Vol. 49, No. 2. pp. 393-399.
@article{52ef94ca1b004a7cbcdddf371a02ebde,
title = "Ropinirole for the treatment of early Parkinson's disease",
abstract = "A prospective, randomized, placebo-controlled, double-blind, parallel- group, 6-month study assessed the efficacy and safety of ropinirole, a nonergoline D2-dopamine agonist, in patients with early Parkinson's disease (n = 241; Hoehn and Yahr stages I to III) with limited or no prior dopaminergic therapy. Patients (mean age, 62.8 years), stratified by concomitant use of selegiline, were randomized to ropinirole (n = 116) or placebo (n = 125). The starting dose of ropinirole was 0.25 mg tid with titration to at least 1.5 mg tid (maximum dose, 8 mg tid). Primary efficacy endpoint was the percentage improvement in Unified Parkinson's Disease Rating Scale (UPDRS) motor score. Ropinirole-treated patients had a significantly greater percentage improvement in UPDRS motor score than patients who received placebo (+24{\%} vs -3{\%}; p < 0.001). Ropinirole was well tolerated and patient withdrawals were infrequent. Most adverse experiences were related to peripheral dopaminergic activity. Ropinirole monotherapy is an effective and well-tolerated therapeutic option for treatment of early Parkinson's disease.",
author = "Adler, {C. H.} and Sethi, {K. D.} and Hauser, {R. A.} and Davis, {T. L.} and Hammerstad, {J. P.} and J. Bertoni and Taylor, {R. L.} and J. Sanchez-Ramos and O'Brien, {C. F.}",
year = "1997",
month = "1",
day = "1",
doi = "10.1212/WNL.49.2.393",
language = "English (US)",
volume = "49",
pages = "393--399",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Ropinirole for the treatment of early Parkinson's disease

AU - Adler, C. H.

AU - Sethi, K. D.

AU - Hauser, R. A.

AU - Davis, T. L.

AU - Hammerstad, J. P.

AU - Bertoni, J.

AU - Taylor, R. L.

AU - Sanchez-Ramos, J.

AU - O'Brien, C. F.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - A prospective, randomized, placebo-controlled, double-blind, parallel- group, 6-month study assessed the efficacy and safety of ropinirole, a nonergoline D2-dopamine agonist, in patients with early Parkinson's disease (n = 241; Hoehn and Yahr stages I to III) with limited or no prior dopaminergic therapy. Patients (mean age, 62.8 years), stratified by concomitant use of selegiline, were randomized to ropinirole (n = 116) or placebo (n = 125). The starting dose of ropinirole was 0.25 mg tid with titration to at least 1.5 mg tid (maximum dose, 8 mg tid). Primary efficacy endpoint was the percentage improvement in Unified Parkinson's Disease Rating Scale (UPDRS) motor score. Ropinirole-treated patients had a significantly greater percentage improvement in UPDRS motor score than patients who received placebo (+24% vs -3%; p < 0.001). Ropinirole was well tolerated and patient withdrawals were infrequent. Most adverse experiences were related to peripheral dopaminergic activity. Ropinirole monotherapy is an effective and well-tolerated therapeutic option for treatment of early Parkinson's disease.

AB - A prospective, randomized, placebo-controlled, double-blind, parallel- group, 6-month study assessed the efficacy and safety of ropinirole, a nonergoline D2-dopamine agonist, in patients with early Parkinson's disease (n = 241; Hoehn and Yahr stages I to III) with limited or no prior dopaminergic therapy. Patients (mean age, 62.8 years), stratified by concomitant use of selegiline, were randomized to ropinirole (n = 116) or placebo (n = 125). The starting dose of ropinirole was 0.25 mg tid with titration to at least 1.5 mg tid (maximum dose, 8 mg tid). Primary efficacy endpoint was the percentage improvement in Unified Parkinson's Disease Rating Scale (UPDRS) motor score. Ropinirole-treated patients had a significantly greater percentage improvement in UPDRS motor score than patients who received placebo (+24% vs -3%; p < 0.001). Ropinirole was well tolerated and patient withdrawals were infrequent. Most adverse experiences were related to peripheral dopaminergic activity. Ropinirole monotherapy is an effective and well-tolerated therapeutic option for treatment of early Parkinson's disease.

UR - http://www.scopus.com/inward/record.url?scp=0030804074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030804074&partnerID=8YFLogxK

U2 - 10.1212/WNL.49.2.393

DO - 10.1212/WNL.49.2.393

M3 - Article

VL - 49

SP - 393

EP - 399

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 2

ER -